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Degradation and remodeling of the extracellular matrix (ECM) is
an essential step in tumour cell migration, invasion and metastasis.
This process is mediated mainly by two families of proteolytic
enzymes, namely components of the plasminogen activation
system, and the matrix metalloproteinases (MMPs) (Stetler
Stevenson et al, 1993). MMPs are a rapidly growing family of
structurally related enzymes that degrade components of the ECM.
Based on their structure and substrate specificity, they are gener-
ally classified into different groups of closely related members,
including collagenases (MMP-1, MMP-8, MMP-13), gelatinases
(MMP-2 and MMP-9), stromelysins (MMP-3, MMP-10, 
MMP-11), metalloelastase (MMP-12), (MMP-18), (MMP-19),
matrilysin (MMP-7), enamelysin (MMP-20), the newly dis-
covered MMP-23, and five membrane-type MMPs. In contrast to
the soluble MMPs, these recently discovered MT-MMPs possess a
transmembrane domain, resulting in cell surface expression (Sato
et al, 1994). Most MMPs are secreted from cells in latent forms
(proMMPs). Conversion of proMMPs to functionally active forms
requires a specific multistep activation process (Nagase, 1997).
MMP activity is further modulated by a family of naturally occur-
ring tissue inhibitors of matrix metalloproteinases (TIMPs), of
which at least four different types (TIMP-1 to TIMP-4) have been
identified (Gomez et al, 1997). TIMPs bind either proMMPs or
active MMPs, thereby inhibiting the autocatalytic activation of
latent enzymes, as well as the proteolytic capacity of active
proteinases. The balance between levels of activated MMP and
free inhibitors determines overall MMP activity (Gomez et al,
1997).
Expression of MMPs and TIMPs changes during the progres-
sion of normal cells towards malignancy. Elevated secretion of
MMPs by tumour cells has been demonstrated in a variety of
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Summary Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are involved in tumour progression and metastasis. In this
study, we investigated the in vitro and in vivo expression patterns of MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1 and TIMP-2 mRNA and protein
in a previously described human melanoma xenograft model. This model consists of eight human melanoma cell lines with different
metastatic behaviour after subcutaneous (s.c.) injection into nude mice. MMP-1 mRNA was detectable in all cell lines by reverse transcription
polymerase chain reaction (RT-PCR), but the expression was too low to be detected by Northern blot analysis. No MMP-1 protein could be
found using Western blotting. MMP-2 mRNA and protein were present in all cell lines, with the highest expression of both latent and active
MMP-2 in the highest metastatic cell lines MV3 and BLM. MMP-3 mRNA was expressed in MV3 and BLM, and in the non-metastatic cell line
530, whereas MMP-3 protein was detectable only in MV3 and BLM. None of the melanoma cell lines expressed MMP-9. TIMP-1 and TIMP-2
mRNA and protein, finally, were present in all cell lines. A correlation between TIMP expression level and metastatic capacity of cell lines,
however, was lacking. MMP and TIMP mRNA and protein expression levels were also studied in s.c. xenograft lesions derived from a
selection of these cell lines. RT-PCR analysis revealed that MMP-1 mRNA was present in MV3 and BLM xenografts, and to a lesser extent in
530. Positive staining for MMP-1 protein was found in xenograft lesions derived from both low and high metastatic cell lines, indicating an in
vivo up-regulation of MMP-1. MMP-2 mRNA was detectable only in xenografts derived from the highly metastatic cell lines 1F6m, MV3 and
BLM. In agreement with the in vitro results, the highest levels of both latent and activated MMP-2 protein were observed in MV3 and BLM
xenografts. With the exception of MMP-9 mRNA expression in 530 xenografts, MMP-3, MMP-9, and TIMP-1 mRNA and protein were not
detectable in any xenograft, indicating a down-regulated expression of MMP-3 and TIMP-1 in vivo. TIMP-2 mRNA and protein were present
in all xenografts; interestingly, the strongest immunoreactivity of tumour cells was found at the border of necrotic areas. Our study
demonstrates that of all tested components of the matrix metalloproteinase system, only expression of activated MMP-2 correlates with
increased malignancy in our melanoma xenograft model, corroborating an important role of MMP-2 in human melanoma invasion and
metastasis. © 1999 Cancer Research Campaign
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cancers (Coussens and Werb, 1996; Chambers and Matrisian,
1997), and the resulting imbalance between MMPs and their
specific inhibitors has been shown to play an important role in
tumour growth and invasion (Stetler Stevenson et al, 1993;
Chambers and Matrisian, 1997). In cultured human melanoma
cells elevated expression of MMP-1, MMP-2, and MMP-9 has
been shown to be correlated with migration and invasion
(MacDougall et al, 1995; Ray and Stetler Stevenson, 1995; Durko
et al, 1997). Increased expression of TIMP-1, TIMP-2 and TIMP-
3 was able to inhibit these processes (Khokha et al, 1992;
Montgomery et al, 1994; Imren et al, 1996; Ahonen et al, 1998;
Valente et al, 1998). In human melanocytic lesions a positive
correlation between tumour progression and MMP-2 expression
level was demonstrated (Vaisanen et al, 1996, 1998). Increased
expression of MMP-9, on the other hand, was found mainly in
radial growth phase of primary melanoma, indicating that MMP-9
expression correlates with early invasion of melanoma (van den
Oord et al, 1997).
In the present study we investigated the expression of MMP-1, 
-2, -3, -9, TIMP-1 and TIMP-2 mRNA and protein in a previously
described xenograft model consisting of eight human melanoma
cell lines with different metastatic capacity after subcutaneous
(s.c.) injection into nude mice (van Muijen et al, 1991a, 1991b;
Westphal et al, 1997). We show for the first time that increased
expression of activated MMP-2 is correlated with melanoma
progression, indicating that activated MMP-2 may be required for
melanoma invasion and metastasis.
MATERIALS AND METHODS
Cell lines and culture conditions
Melanoma cell lines 530, 1F6, MV1, M14, Mel57, 1F6m, MV3
and BLM have been described previously (van Muijen et al,
1991a, 1991b). All cell lines were derived from surgically
removed human metastases, and form local tumours after s.c.
injection into nude mice. The xenografts differ in growth rate and
capacity to form spontaneous lung metastases, as described 
previously (Westphal et al, 1997) (Table 1). Melanoma cell line
M24met was kindly provided by Dr B Mueller (The Scripps
Institute, La Jolla, CA, USA), and served as a positive control for
MMP-1 expression. Human fibrosarcoma cell line HT1080
(American Type Culture Collection, Rockville, MD, USA) served
as a positive control for MMP-9 expression. All cell lines were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
(Biowhittaker, MD, USA), supplemented with 10% fetal calf
serum (FCS) (Integro, Zaandam, The Netherlands) and
gentamycin (40 mg ml–1, Gibco-BRL, Gaithersburg, MD, USA) in
an atmosphere of 95% humidified air and 5% carbon dioxide at
37°C. Cells were detached from tissue-culture flasks with 0.05%
trypsin, 0.02% EDTA and 0.1% glucose in phosphate-buffered
saline (PBS) for 2 min at 37°C.
Xenografts in nude mice and rats
Human melanoma cell lines were xenografted in BALB/c nu/nu
mice kept under aseptic conditions according to NIH guidelines. A
Table 1 Biological characteristics of human melanoma cell lines
Cell lines In vitro In vivo Metastases Speed of metastases
growth rate growth ratea formationa formationa
530 Slow Slow No Not applicable
1F6 Slow Medium No Not applicable
MV1 Fast Medium Yes Weeks/month
M14 Fast Medium Yes Weeks/month
Me57 Fast Medium Yes Weeks/month
1F6m Medium Medium Yes Weeks/month
MV3 Fast Fast Yes Days/weeks
BLM Fast Fast Yes Days/weeks
aAfter s.c. inoculation into nude mice.
Table 2 Sequences of PCR primer sets used (Grant et al, 1996)
Factor Primer sequences Product size
MMP-1 5¢-CGACTCTAGAAACACAAGAGCAAGA-3¢ (sense) 786-bp
5¢-AAGGTTAGCTTACTGTCACACGCTT-3¢ (antisense)
MMP-2 5¢-GTGCTGAAGGACACACTAAAGAAGA-3¢ (sense) 580-bp
5¢-TTGCCATCCTTCTCAAAGTTGTAGG-3¢ (antisense)
MMP-3 5¢-AGATGCTGTTGATTCTGCTGTTGAG-3¢ (sense) 515-bp
5¢-ACAGCATCAAAGGACAAAGCAGGAT-3¢ (antisense)
MMP-9 5¢-CACTGTCCACCCCTCAGAGC-3¢ (sense) 243-bp
5¢-GCCACTTGTCGGCGATAAGG-3¢ (antisense)
TIMP-1 5¢-ATCCTGTTGTTGCTGTGGCTGATAG-3¢ (sense) 667-bp
5¢-TGCTGGGTGGTAACTCTTTATTTCA-3¢ (antisense)
TIMP-2 5¢-AAACGACATTTATGGCAACCCTATC-3¢ (sense) 405-bp
5¢-ACAGGAGCCGTCACTTCTCTTGATG-3¢ (antisense)
b2-m 5¢-GCTCTGTCTCTCGTGGTC-3¢ (sense) 136-bp
5¢-GCATGGTCCACAGTTCTTG-3¢ (antisense)776 UB Hofmann et al
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total of 3–5 ´ 106 cells of human melanoma cell lines 530, 1F6,
Mel57, 1F6m, MV3 and BLM were injected s.c. into the flank of
nude mice. In order to be able to use mouse monoclonal antibodies
for immunohistochemistry, 1F6 and BLM xenografts were also
grown in nude rats. The animals were sacrificed when the tumour
had a diameter of approximately 1 cm. Parts of the tumours were
snap-frozen and stored in liquid nitrogen.
RNA isolation
Total RNA from each cell line was isolated using the RNeasy Mini
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. Typically, 1 ´ 107 cells were used for each isolation,
yielding 50–100 mg RNA. For RNA extraction from tissue
samples, frozen sections from xenografts derived from melanoma
cell lines were used. Total RNA was isolated after disrupting at
least one 20-mm frozen section in 1 ml RNAzolBTM (Campro,
Veenendaal, The Netherlands) using a pestle. Melanin and DNA
were removed from RNA samples using the RNeasy kit.
RT-PCR analysis
A total of 0.5 mg of RNA was reverse-transcribed with the 1st
Strand cDNA Synthesis Kit for reverse transcription polymerase
chain reaction (RT-PCR) (Boehringer Mannheim, Penzberg,
Germany) using random hexadeoxynucleotide primers according
to the manufacturer’s instructions. One microlitre aliquots of the
reverse-transcribed cDNA was subjected to PCR, using PCR
buffer IV (20 mM (NH4)2SO4, 75 mM Tris–HCl pH 9, 0.1% Tween)
0.2 M dNTPs, 2 pmoles of each primer, 1.5 mM magnesium chlo-
ride and 0.15 units of Thermoperfectplus DNA polymerase
(Integro, Zaandam, The Netherlands). Water was added to a final
volume of 25 ml. Each PCR was performed for 30 cycles (45 s at
94°C, 1 min at 59°C, 1 min 30 s at 72°C), preceeded by a denatu-
ration step at 94°C for 3 min, and terminated with an elongation
step at 72°C for 5 min. PCR products were visualized on 2%
agarose gels containing ethidium bromide. As positive control for
the RT-PCR procedure we used b2-microglobulin (b2-m).
Incubations in which cDNA was omitted were used as negative
controls. The PCR procedure was performed at least twice for each
sample. The sequences of the human specific PCR primers are
given in Table 2.
Northern blot analysis
Aliquots of 5 mg of total RNA extracted from each cell line were
electrophoresed on a 1% agarose gel containing MOPS/
paraformaldehyde and transferred to a nylon membrane
(Boehringer Mannheim) by capillary blotting in 20 ´ standard
saline citrate (SSC) according to standard protocols. Levels of 28S
and 18S RNA were used as a control for RNA integrity and
loading consistency. RNA was fixed to the membrane by baking
for 30 min at 120°C. Probes for MMP-1 and MMP-2 were 1.4 kb
and 2.6 kb cDNA fragments (gifts from Dr R Hanemaaijer
(Gaubius Laboratory IVVO-TNO, Leiden, The Netherlands)),
cloned in Bluescript KS vector and isolated from overnight
cultures with the WizardTM Miniprep Kit (Promega, Madison, WI,
USA). DIG-labelled DNA probes were produced by performing
PCR on cloned DNA fragments in the presence of 0.7 mM DIG-
labelled dUTP in PCR DIG labelling mix (Boehringer Mannheim).
DNA probes were purified with the QIAquick PCR Purification
Kit (QIAGEN, Hilden, Germany) following the manufacturer’s
instructions. Blots were hybridized overnight at 50°C at a probe
concentration of 40 ng ml–1 in Easyhyb hybridization buffer
(Boehringer Mannheim). Blots were washed twice for 5 min at
room temperature in 2 ´ SSC 0.1% sodium dodecyl sulphate
(SDS), once in 0.5 ´ SSC 0.1% SDS at 68°C for 15 min, and
finally in 0.1 ´ SSC 0.1% SDS for 15 min at 68°C. The
membranes were developed by chemiluminescence detection with
CSPD or CDP-Star (Boehringer Mannheim), and exposed to
Kodak X-Omat-AR film.
Western blot analysis
Serum-free conditioned medium (SFCM) was generated by
washing cells three times with PBS, followed by incubation
overnight in serum-free medium. SFCM derived from 1 ´ 107 cells
from each cell line was used. Western blot analysis was performed
according to standard protocols. Briefly, 12 ml samples of 10 times
concentrated (Centricon 10 microconcentrator; Amicon, Beverly,
MA, USA) SFCM were run on 10% polyacrylamide gel. Samples
were incubated for 5 min at 95°C in the presence of 10% b-
mercaptoethanol prior to electrophoresis. After electrophoresis,
samples were electroblotted onto nitrocellulose (Schleier &
Schuell, Dassel, Germany). Blots were blocked for 30 min in
blocking solution (Boehringer Mannheim) at room temperature
and then incubated overnight with 1 mg ml–1 of primary antibody
in blocking solution. After washing with PBS 0.05% Tween-20,
membranes were incubated for 2 h at room temperature with a
rabbit anti-mouse peroxidase-labelled secondary antibody (Dako,
Denmark) in blocking solution. After additional washes, binding
of peroxidase-labelled antibody was visualized by chemilumines-
cence (Boehringer Mannheim), according to the manufacturer’s
protocol.
Gelatin zymography
Zymography was performed according to standard protocols.
Aliquots of unconcentrated SFCM (5 ml) were diluted 1:1 in
sample-buffer (62.5 mM Tris–HCl (pH 6.8), 8.8% glycerol, 2%
(w/v) SDS, 0.05% bromophenol blue). After heating at 60°C for
20 min, samples were electrophoresed at 4°C on a 7.5% SDS-
polyacrylamide gel containing 0.5 mg ml–1 gelatin. After electro-
phoresis, gels were washed three times in 2.5% Triton X-100 for
10 min to remove SDS. After rinsing twice in substrate buffer (50
mM Tris–HCl, pH 7.8, containing 5 mM calcium chloride and 0.1%
Triton X-100), the gels were incubated at 37°C for 18 h in the
same buffer under gentle agitation. Gels were stained for 45 min in
40% methanol 10% glacial acetic acid containing 0.1% (w/v)
Coomassie brilliant blue R250 and re-stained in the same solution
without Coomassie brilliant blue. Activation of MMP-2 and
MMP-9 was achieved by incubating samples before zymography
with 1 mM p-aminophenylmercuric acetate (APMA) at 37°C for 2
h. Latent proMMP-2 (Mr 66 000) and proMMP-9 (Mr 92 000) as
well as activated MMP-2 (Mr 62 000) and MMP-9 (Mr 84 000)
were identified by comparing them to known gelatinolytic activity
from conditioned medium from HT1080 cells (Sato et al, 1994)
and control samples containing MMP-2 and MMP-9 protein
(Oncogene Research Products, Cambridge, MA, USA) with and
without APMA pretreatment. For zymography analysis of
xenografts, 4 serial tissue cryostat sections (10-mm) were homo-
genized in 4 ´ sample-buffer, centifuged for 1 min at 10 000 g, andMMP-2 expression and melanoma progression 777
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pellets were incubated at 37°C for 30 min. Samples were mixed
with distilled water (1:1) and heated at 60°C for 20 min. After
centrifugation (1 min, 10 000 g) pellets were discarded and super-
natants were subjected to zymographic analysis. Zymography was
performed at least twice for each sample.
Antibodies
For Western blot analysis mouse monoclonal antibodies (mAbs)
(Oncogene Research Products, Cambridge, MA, USA) against
MMP-1 (clone 41-1E5), MMP-2 (clone 42-5D11), MMP-3 (clone
55-2A4), MMP-9 (clone 56-2A4), TIMP-1 (clone 7-6C1) and
TIMP-2 (clone T2-101) were used. For immunohistochemistry a
rabbit polyclonal antibody against human MMP-2 (# AB809,
Chemicon International Inc, Temecula, CA, USA), sheep poly-
clonal antibodies against MMP-3 (# PH112, The Binding Site
Limited, Birmingham, UK), MMP-9 (# PH163, The Binding Site
Limited, Birmingham, UK), and mouse monoclonal antibodies
(Oncogene Research Products, Cambridge, MA, USA) against
MMP-1 (clone 41-1E5), TIMP-1 (clone 7-6C1) and TIMP-2
(clone T2-101) were used. A polyclonal rabbit antibody against
human u-PA (Dako, Carpinteria, CA, USA) (Ferrier et al, 1998)
was used as positive control.
Immunohistochemistry
For immunohistochemistry 4-mm cryostat serial sections of
xenograft lesions were used. At least three different xenografts per
cell line were analysed. Sections were fixed for 10 min at room
temperature in aceton with 0.15% hydrogen peroxide to inactivate
endogenous peroxidase, followed by incubation overnight with
primary antibodies in humidified chamber at 4°C. Subsequent
steps were performed at room temperature. Prior to incubation
with a biotinylated goat anti-rabbit, horse anti-mouse or goat anti-
sheep secondary antibodies (Vector Laboratories, Burlingame,
CA, USA) for 30 min, the avidin–biotin blocking kit (Vector
Laboratories) was used according to the manufacturer’s protocol.
Forty-five minutes after addition of the avidin–biotin–peroxidase
complex (Vectastain Elitekit, Vector Laboratories), sections were
developed with amino-ethyl carbazol (AEC), and counterstained
with Meyer’s haematoxylin. An incubation where the first anti-
body was omitted served as negative control.
RESULTS
We investigated the expression of MMP-1, MMP-2, MMP-3,
MMP-9, TIMP-1 and TIMP-2 in a xenograft model consisting of
eight human melanoma cell lines with different metastatic behav-
iour after s.c. inoculation into nude mice. Cell lines 530 and 1F6
are non- or sporadically metastasizing, whereas MV1, M14,
Mel57, 1F6m, MV3 and BLM are frequently metastasizing. Of
these six lines, MV3 and BLM tumours grow faster, and generate
lung metastases much sooner compared to the other four cell lines
(Westphal et al, 1997) (Table 1).
MMP and TIMP mRNA in human melanoma cell lines
RT-PCR analysis detected MMP-1, MMP-2, TIMP-1 and TIMP-2
mRNA in all melanoma cell lines. MMP-3 mRNA was only
produced by the very aggressive cell lines MV3 and BLM and,
remarkably, also by the non-metastatic cell line 530. MMP-9
mRNA, on the other hand, was not detectable in any cell line; the
390-bp PCR band represents amplified DNA instead of RNA. A
control RT reaction for MMP-9 without reverse transcriptase was
performed (data not shown). The results of the RT-PCR analysis
are shown in Figure 1. In order to make a quantitative comparison
of MMP-1 and MMP-2 mRNA levels, we performed Northern blot
analysis. MMP-1 mRNA levels were too low to be detected in
Northern blotting, whereas MMP-2 mRNA levels were clearly
elevated in the highly metastatic cell lines MV3 and BLM
(Figure 2).
MMP and TIMP protein in human melanoma cell lines
MMP and TIMP protein levels were determined by Western blot
analysis of 10 ´ concentrated SFCM derived from 1 ´ 107 cells
(Figure 3). In agreement with our Northern blot results, MMP-1
protein was undetectable in our panel of cell lines. MMP-2 protein
could be detected in all cell lines, but markedly increased in the
highly metastatic cell lines MV3 and BLM. MMP-3 protein was
present in SFCM of the cell lines MV3 and BLM but, despite
MMP-3 mRNA expression, MMP-3 protein was not detectable in
SFCM from cell line 530. In agreement with the results on mRNA
no MMP-9 protein was detectable in any cell line. Western blots
for TIMP-1 and TIMP-2 showed protein expression in all cell
lines. Although the expression levels of TIMP-1 and TIMP-2
protein markedly differed among cell lines, there was no evident
correlation with metastatic capacity in the xenograft model.
Activation status of MMP-2 was studied by zymography
analysis of unconcentrated SFCM. Pretreatment of SFCM with
p-APMA has been shown to induce the autocatalytic removal of
the amino-terminal domain of the proMMPs, resulting in conver-
sion to the active form. The latent proMMP-2 was detectable in all
cell lines, but expression of functionally active MMP-2 was
restricted to the highly metastatic cell lines MV3 and BLM.
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Figure 1 RT-PCR analysis of MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1
and TIMP-2 mRNA expression in human melanoma cell lines. An incubation
without template cDNA was used as negative control. M24met or HT1080
mRNA were used as positive controls. PCR was performed at least twice for
each component and each cell line. Lengths of the PCR products (bp) are
indicated778 UB Hofmann et al
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Addition of p-APMA resulted in an expression of active MMP-2
in all cell lines. Consistent with the Western blot results MMP-9
was not detectable in our melanoma cell line panel (Figure 4).
MMP and TIMP mRNA in melanoma xenografts
Frozen tissue sections from melanoma xenograft lesions derived
from cell lines 530, Mel57, 1F6m, MV3 and BLM were used to
determine mRNA expression of MMPs and TIMPs in vivo (Figure
5). The RT-PCR data of 1F6, MV1 and M14 are not shown,
because melanin present in the xenografts copurified with the
RNA, and caused strong inhibition of the RT-reaction (Westphal et
al, manuscript in preparation). Expression of MMP-1 mRNA was
found in MV3 and BLM xenografts and, to a lesser extent, in 530
tumours. MMP-2 mRNA was detectable in 1F6m, MV3 and BLM
xenografts. MMP-3 and TIMP-1 mRNA were not expressed in any
xenografts. A very low MMP-9 mRNA expression was observed
in 530 xenografts. TIMP-2 mRNA was detectable in all samples.
MMP and TIMP protein in melanoma xenografts
We used immunohistochemistry to investigate the expression of
MMP and TIMP proteins in vivo. Mice xenografts from cell lines
530, Mel57, 1F6m, MV3 and BLM were stained with polyclonal
antibodies. Rat xenografts from 1F6 and BLM were used for
immunohistochemistry with mouse monoclonal antibodies. A
moderate granular cytoplasmatic staining for MMP-1 was
detectable in all tumour cells in 1F6 and BLM xenografts. In these
lesions the stromal septa separating tumour cell nests showed also
a strong immunoreactivity (data not shown). Tumour cells in 530,
1F6 and Mel57 xenografts were MMP-2-negative, whereas some
fibroblasts and tumour surrounding stromal cells were MMP-2-
positive (Figure 6A). In 1F6m xenografts a moderate granular and
cytoplasmatic staining of tumour cells was found. A heteroge-
neous strong granular cytoplasmatic staining pattern was observed
in tumour cells in MV3 and BLM xenografts (Figure 6B).
Remarkably, immunoreactivity of tumour cells increased at the
growth or invasive front of 1F6m, MV3 and BLM xenografts
(Figure 6C). No staining of tumour cells was observed for MMP-3,
MMP-9 and TIMP-1, whereas macrophages of mouse origin
surrounding the tumours showed a strong immunoreactivity for
both MMP-3 and MMP-9 (Figure 6D). A strong immunoreactivity
against TIMP-1 was found in blood vessels of rat tissue adjacent to
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Figure 3 Western blot analysis of MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1
and TIMP-2 expression in human melanoma cell lines. M24met and HT1080
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Figure 2 Northern blot analysis of MMP-1 and MMP-2 expression in human
melanoma cell lines. M24met mRNA was used as a positive control for
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tumours (Figure 6E). In all studied xenografts tumour cells were
positive for TIMP-2 protein. The tumour cells in the periphery of
necrotic areas stained stronger (Figure 6F).
Finally, we performed zymography to determine the activation
status of MMP-2 protein expression in xenografts. The latent form
of MMP-2 (Mr 66 000) was detectable in all studied xenografts.
Expression of MMP-2 protein in 530 and Mel57 xenografts is due
to mouse origin. In these lesions we found a strong immunoreac-
tivity for MMP-2 only in macrophages surrounding the tumours.
The Mr 62 000 band representing the activated form of MMP-2,
however, showed increased expression levels in MV3 and BLM
xenografts (Figure 7).
DISCUSSION
Cutaneous melanoma is characterized by a high capacity for inva-
sion and metastasis. In this process degradation of the ECM and
basement membranes by proteolytic enzymes is an essential step,
in which MMPs play an important role (Stetler Stevenson et al,
1993; Mueller, 1996). Overexpression of MMP-1, MMP-2 and
MMP-9 has been implicated in the migration and invasion of
melanoma cells (MacDougall et al, 1995; Ray and Stetler
Stevenson, 1995; Durko et al, 1997). The relative contribution of
these enzymes to melanoma invasion and metastasis, however, is
not fully understood. We used a well-defined human melanoma
xenograft model to investigate the expression profiles of MMP-1,
MMP-2, MMP-3, MMP-9, TIMP-1 and TIMP-2, and their correla-
tion to melanoma progression.
Compared with the cultured cell lines where MMP-1 protein
was undetectable, expression was up-regulated in xenograft
lesions. A moderate staining for MMP-1 was found in xenografts
of both the non-metastatic cell line 1F6 and the highly metastatic
cell line BLM. A strong immunoreactivity for MMP-1 was
detectable in stromal septa surrounding the tumour nests, indi-
cating that host mechanisms may be involved in up-regulated
expression of MMP-1 in vivo. It has been demonstrated that
expression of MMPs in tumour surrounding stromal cells is an
important factor in the process of tumour progression
(MacDougall et al, 1995). In another study expression of MMP-1
has been shown to correlate with invasive capacity of melanomas
(Woolley et al, 1980). In agreement with this, Durko et al (1997)
showed that invasion of human melanoma cells through type VI
collagen and a reconstituted basement membrane (Matrigel) was
dependent on expression of MMP-1.
An increased expression of MMP-2 has been shown to be asso-
ciated with tumour progression in several tumour types (Nomura
et al, 1995; Lambert et al, 1998). In melanocytic lesions, a
correlation between MMP-2 protein expression and decreased
architectural organization, increased atypia, and haematogenous
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Figure 4 Zymographic analysis of in vitro MMP-2 and MMP-9 expression. Aliquots of SFCM derived from melanoma cell lines or HT1080 cells (positive
control) were incubated in the presence (+) or absence (–) of p-APMA prior to analysis. Purified MMP-2 and MMP-9 protein with (+) and without (–) p-APMA
pretreatment were used as controls (right lanes)
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Figure 5 Expression of MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1 and
TIMP-2 mRNA in xenografts. mRNA from M24met or HT1080 cell lines were
used as positive controls. PCR was performed at least twice with the same
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metastasis was described (Vaisanen et al, 1996). In another study
by the same group (Vaisanen et al, 1998), a positive correlation
between high level of MMP-2 protein expression and poor prog-
nosis in melanoma patients was found. Consistent with this, we
found clearly elevated expression level of MMP-2 mRNA and
protein in the most aggressive cell lines MV3 and BLM as well as
in the corresponding xenografts. The discrepancy in the levels of
MMP-2 mRNA in vitro, as determined by RT-PCR and Northern
blot is most likely due to the fact that the results of RT-PCR repre-
sent the end-point of the reaction, making a quantitative compar-
ison of samples impossible. Since the ability of a tumour to
activate MMP-2 may be more important than MMP-2 expression
per se, we also studied MMP-2 activation status. We found that
activated MMP-2 of tumour cells was restricted to the most
aggressive cell lines MV3 and BLM, both in vitro and in vivo. In
line with this, activation of MMP-2 was shown to correlate with
malignant progression in brain tumours (Yamamoto et al, 1996),
lung (Tokuraku et al, 1995) and gastric carcinomas (Nomura et al,
1995).
The specific mechanism of proMMP-2 activation is not fully
understood. It has been demonstrated that increased expression of
MT1-MMP results in activation of MMP-2 on the cell surface,
which is required for cell invasion when localized to invadopodia
of human melanoma cells (Nakahara et al, 1997). MMP-2 activity,
however, is also regulated by the amount of TIMP-2 present (Butler
et al, 1998). On one hand, TIMP-2 may act as a specific inhibitor of
MMP-2, and has been shown to inhibit tumour growth and tumour
cell invasion (Montgomery et al, 1994; Imren et al, 1996; Valente et
al, 1998). On the other hand, TIMP-2 may be directly involved in
MMP-2 activation by forming a complex with MT1-MMP that
functions as a receptor for MMP-2 at the cell surface (Strongin et
al, 1995; Butler et al, 1998; Zucker et al, 1998). A coordinated
expression of MMP-2, MT1-MMP and TIMP-2 resulting in an acti-
vation of MMP-2 was also reported to be correlated with malignant
progression in other human cancers (Kanayama et al, 1998;
Lambert et al, 1998). We found TIMP-2 mRNA and protein
expressed in all cell lines in vitro and in vivo. Whether in our
xenograft model TIMP-2 acts as a MMP-2 inhibitor, as a MMP-2
co-activator, or both, remains to be determined.
The role of MMP-9 in melanoma progression is unclear.
Whereas we found virtually no expression of MMP-9 mRNA and
protein in tumour cells in vitro and in vivo, MMP-9 expression
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Figure 6Immunohistochemical staining of MMPs and TIMPs in xenografts.
(A) Staining of MMP-2 in 1F6 xenograft. Note MMP-2 expression in
fibroblasts (arrow), whereas tumour cells are negative. (B) MMP-2
expression in MV3 xenograft. Note heterogeneous strong staining of tumour
cells. (C) BLM xenograft stained for MMP-2. Note a stronger expression of
MMP-2 at the tumour border. (D) Staining of MMP-3 in Me 57 xenograft
showing a strong positivity of macrophages surrounding the tumour (arrows).
(E) TIMP-1 expression in BLM xenograft. Note negative staining of tumour
cells, whereas smooth muscle cells in the wall of blood vessels stained
positive. (F) Staining of TIMP-2 in BLM xenograft showing a moderate
granular staining of tumour cells. Note that tumour cells in the periphery of
necrotic areas stained stronger. Nuclear staining with haematoxylin.
Magnification: bar = 30mm in A, B, D, E; bar = 60mm in C, F
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Figure 7   Zymographic analysis of xenograft tissue extracts. MV3 and BLM xenografts express increased levels of active MMP-2MMP-2 expression and melanoma progression 781
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was described in seven melanoma cell lines derived from
advanced stage melanoma, but not from early stage melanoma
(MacDougall et al, 1995). In contrast, van den Oord et al (1997)
found MMP-9 expression in human melanoma cells in the radial
growth phase of primary melanoma with thickness < 1.6 mm, but
not in melanoma metastases. In line with this, the lack of MMP-9
expression in our panel of cell lines may be attributed to the fact
that all lines are derived from human melanoma metastases. Our
data on MMP-9 expression taken together with several reports
based on immunohistochemistry and in situ hybridization indicate
that MMP-9 may not expressed by tumour cells but predominantly
by tumour surrounding stromal cells (Heppner et al, 1996; Nielsen
et al, 1996; Sugiura et al, 1998).
To the best of our knowledge the expression profile of MMP-3
in melanoma has not yet been studied. MMP-3 protein was shown
to be expressed by the highly metastatic cell lines MV3 and BLM,
suggesting a possible role for MMP-3 in tumour cell invasion and
metastasis. In agreement with this, Sreenath et al (1992) showed
that high levels of MMP-3 expression were associated with
metastatic potential of transformed rat embryo cells. In xenograft
lesions we found no expression of MMP-3 protein in tumour cells,
whereas a strong immunoreactivity was observed in macrophages
and tumour surrounding stromal cells. A similar stromal cell
expression pattern has also been described in other tumour types
as colorectal cancer (Newell et al, 1994). Our observations on
MMP-3 and MMP-9 expression by macrophages and fibroblasts
supports the possible involvement of these cells in melanoma
progression. Studies on MMP expression by stromal cells in
human melanoma are currently in progress.
TIMP-1 serves as a regulatory element of MMP-9 activation
(Gomez et al, 1997; Nagase, 1997), and increased expression of
TIMP-1 inhibits tumour growth, invasion and metastasis of
melanoma cells in vitro and in vivo (Khokha et al, 1992; Khokha,
1994). In our study we found that TIMP-1 was expressed by all
cell lines, but no expression was detectable in xenografts,
indicating that TIMP-1 expression is down-regulated in vivo.
Therefore, the role of this molecule in tumour progression in our
xenograft model appears to be limited.
Although the specific role of the different MMPs in tumour
progression, and the specific activation mechanism of the MMPs
in vivo still remains unclear, our study shows that an increased
expression of activated MMP-2 correlates with metastatic be-
haviour in our xenograft model. Our data taken together with
previous studies strongly implicate an important role for activated
MMP-2 in melanoma progression. Studies on specifically
blocking MMP-2 activity may lead to novel strategies in the
systemic therapy of malignant melanoma.
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